Our data provide mechanistic insights into the clinical activities of inhibitors targeting Btk and/or NF-κB in combination with doxorubicin for treatment of EBV-positive DLBCL, and support the utility of circulating CCL3 or CCL4 as response predictors to combination treatments in DLBCL. This evidence concerns the gene CCL4 and diffuse large B-cell lymphoma.